No CrossRef data available.
Article contents
Administración nasogástrica de risperidona para tratar las ideas delirantes de envenenamiento
Published online by Cambridge University Press: 12 May 2020
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

- Type
- Cartas al director
- Information
- Copyright
- Copyright © European Psychiatric Association 2004
References
Bibliografía
Degenhardt, L, Hall, W. Cannabis and psychosis. Curr Psychiatry Rep 2002;4:191–6.CrossRefGoogle ScholarPubMed
Glass, M. The role of cannabinoids in neurodegenerativo diseases. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:743–65.CrossRefGoogle Scholar
Hambrecht, M, Hafner, H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust NZ J Psychiatry 2000;34:468–75.CrossRefGoogle Scholar
Robinson, S, Winnik, HZ. Severe psychotic disturbances following crasch diet weight loss. Arch Gen Psychiatry 1973;29:559–62.CrossRefGoogle Scholar
Skosnik, PD, Sparz-Glenn, L, Park, S. Cannabis use is associated with schizotypy and attentional dysinhibition. Schizophrenia Res 2001;25:743–65.Google Scholar